Our Successes

Our Successes While many of WAF’s cases remain under seal, some of the settlements in which WAF and its principals have been involved are:

Johnson & Johnson Paid $2.2 Billion to Resolve Off-Label Marketing and Kickback Allegations

J&J agreed to pay more than $2.2 billion to resolve allegations it promoted Risperdal, Invega and Natecor for off-label uses. The company promoted Risperdal for use in children and individuals with mental illness, while knowing that the drug posed health risks to children.

Abbott Labs Paid $1.5 Billion to Resolve Depakote Investigations

Abbott plead guilty to misbranding Depakote by promoting the drug to control agitation and aggression in elderly dementia patients and to treat schizophrenia when neither of these uses was FDA-approved.

Medco Paid $155 Million to Settle False Claims Act

Cases Settled allegations that the company submitted false claims to the government, solicited and accepted kickbacks from pharmaceutical manufacturers to favor their drugs and paid kickbacks to health plans to obtain business.

Cephalon Paid $425 Million For Off-Label Marketing Violations

Settled allegations with the U.S. government related to the illegal off-label marketing of three of its drugs – Actiq, Gabitril and Provigil. Bristol-Myers Squibb Paid $515 Million for Illegal Drug Marketing and Pricing Settled allegations with the U.S. government to resolve a broad array of allegations involving the company’s drug marketing and pricing practices.

Forest Laboratories Paid $170 million For Off-Label Drug Marketing

Settled a Department of Justice investigation into its marketing and promotion of two antidepressants, Celexa and Lexapro.

McKesson Paid $340 Million to Resolve False Claims Allegations

Settled claims that it violated the False Claims Act by reporting inflated pricing information for a large number of prescription drugs, causing Medicaid to overpay for those drugs.